CAMBRIDGE, England, July 8 Funxional Therapeutics Ltd(Funxional) has announced today the successful completion of the first PhaseI study with FX125L, an orally available small molecule which belongs to anew therapeutic class named Broad Spectrum Chemokine Inhibitors (BSCIs).
The Phase I, single ascending dose study was conducted in the UnitedStates. FX125L was well tolerated at all doses studied and no serious adverseevents or subject withdrawals were observed. The pharmacokinetics of FX125Lwas linear over the wide dose range studied and consistent with once-dailyoral dosing for patients.
"We are extremely pleased with the outcome of this initial clinical studywith FX125L," said Konstantinos Efthymiopoulos, CEO of FunxionalTherapeutics. "The results in humans are consistent with the preclinicaldata, suggesting that FX125L has a very wide safety margin, and confirmed theexcellent drug-like profile of FX125L."
About Funxional Therapeutics Ltd.
Funxional Therapeutics is a privately held, clinical stage pharmaceuticalcompany based in Cambridge (UK) which focuses on novel anti-inflammatorytherapies. FXT is managed by a very experienced team and is financed by IndexVentures and Novo A/S, while its shareholders also include Ipsen andCambridge University. FXT has research and office facilities in Cambridge.
For more information about FXT, please visit our web site(http://www.funxionaltherapeutics.com) or contact us by e-mail(email@example.com).
BSCIs are anti-inflammatory compounds with an entirely novel mechanism ofaction that involves the selective interaction with a well-characterizedreceptor, resulting in a potent inhibition of inflammatory cell migration.The compounds are anticipated to have broad applicability in inflammatorydiseases.
BSCIs are one of the three proprietary technology platforms in FXT'sportfolio all of which originated in the University of Cambridge. BSCIs werediscovered based upon a strategy that exploits functional screening todevelop novel new classes of drugs. FX125L is the lead drug candidate in thisnovel class, while other BSCIs have been identified as back up molecules oras candidates for development as topical anti-inflammatory agents.
For enquiries regarding this press release, please contact KonstantinosEfthymiopoulos, CEO of Funxional Therapeutics, at +44-1223-451095.
SOURCE Funxional Therapeutics Limited